Stem Cell Therapeutics Corp. Closes Financing for $2,186,941

NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR DISSEMINATION IN THE UNITED STATES

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT") is pleased to announce
that it has closed the previously announced financing with J.F. Mackie & Company
Ltd. ("J.F. Mackie"). Gross proceeds of $1,138,741 were raised, which includes
the partial exercise of an overallotment option, resulting in 9,489,507 Units
(the "Units") being sold. The Units were sold to the public at a price of $0.12
per Unit, with each Unit consisting of one common share of SCT ("Common Share")
and one common share purchase warrant ("Warrant"). Each Warrant is exercisable
to acquire one additional Common Share at a price of $0.15 per share for 12
months from the closing date. A total commission of $91,099 (8% of gross
proceeds raised) was paid to J.F. Mackie in connection with the brokered
financing. Additionally, J.F. Mackie received 474,475 Broker Warrants. Each
Broker Warrant is exercisable to acquire one Common Share at a price of $0.12
per share for 12 months from the closing date.


Furthermore, SCT reports that the previously announced non-brokered financing
has also been closed. Gross proceeds of $1,048,200 were raised from the issuance
of 8,735,000 Units. A total commission of $74,736 was paid to registered dealers
in connection with the non-brokered financing on the basis of 8% of gross
proceeds by registered brokers.


In total $2,186,941 of gross proceeds were raised in this financing as
consideration for the issuance of 18,224,507 units and SCT intends to use the
net proceeds for general working capital purposes.


All securities issued today have been, and any securities issued on the exercise
of Warrants and Broker Warrants will be, issued with a legend restricting
transfer prior to March 2, 2010.


This press release shall not constitute an offer to sell or the solicitation of
an offer to buy nor shall there be any sale of the securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such
jurisdiction.


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public
biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual property supports
the potential expansion into future clinical programs in numerous neurological
diseases such as traumatic brain injury, multiple sclerosis, Huntington's
disease, Alzheimer's disease, and ALS. 


Today is World Stroke Day. (http://www.world-stroke.org/wsd/) Please take the
time to learn and acknowledge the risk factors for stroke. The goal for this day
is to raise awareness about how to prevent stroke and to prompt individuals,
groups and governments to take action against stroke either at a personal, or
group level. 


For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available.


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. Forward-looking statements in this news release
include, but are not limited to, statements with respect to: the purposes for
which the Company intends to use the net proceeds of the Offering and the
expectations of the Company concerning the timing of obtaining additional
patient recruiting sites for the NTx(TM)-265 stroke trial. These forward-looking
statements involve risk and uncertainties, which may include, but are not
limited to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties related
to the regulatory approval process and other risks detailed from time to time in
the Company's ongoing quarterly and annual reporting.